October 21, 2020 -- InvestorsHub NewsWire -- via pennymillions/PAOG -- PAO Group, Inc. (USOTC: PAOG) has a patent backed drug, RespRx, for treating lung diseases to include a potential treatment for COVID-19.

PAOG - New Independent CBD Research Appears To Support PAOG RespRx Research

PAOG announced yesterday that the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).

On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.

Big FDA application news could see this sub penny make a major breakout to over a penny.

Other stocks on the move include CTYX, AABB and SING.

SOURCE: pennymillions/PAOG

Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Kali (CE) Charts.
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Kali (CE) Charts.